Evaluation of the Vsling™ Device for Heart Failure Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical evaluation focuses on the Vsling™ device, which is designed for ventricular repair in patients suffering from heart failure with reduced ejection fraction. The study is prospective, multi-center, and open-label, assessing the feasibility, safety, and performance of the device in patients with significant left ventricular dilation. Participants will be monitored for their heart function and overall health outcomes following the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age≥18 years
2. Left ventricular end diastolic diameter is greater than or equal to 55mm
3. Ejection fraction ≥20% and ≤40%
4. FMR grade ≤ 2+ (≤ mild FMR) as defined by the guidelines of the American society of echocardiography (via a transthoracic or transesophageal echo)
5. End-systolic Interpapillary muscle distance ≥ 20mm
6. NYHA class II-IVa
7. Cardiomyopathy of ischemic or non-ischemic origins
8. Understands the nature of the study and procedure and able to provide written informed consent

Exclusion Criteria:

1. Any evidence of structural (chordal or leaflet) mitral lesions
2. Ventricular tachycardia or ventricular fibrillation within 6 months prior to inclusion in this study
3. Prior mitral valve repair or replacement
4. ICD/CRT/cardiac pacemaker leads implanted within 3 months prior to inclusion in this study
5. Clinical signs of cardiogenic shock within 30 days prior to inclusion in this study
6. Anatomy that, in the opinion of the interventionalist, prevents safe passage of the Vsling™ catheter(s).
7. Severe aortic stenosis
8. Severe, massive, or torrential tricuspid regurgitation requiring surgical or transcatheter repair
9. Known fixed pulmonary hypertension with PA systolic pressure \>70 mmHg not responsive to vasodilator therapy
10. ST segment elevation myocardial infarction within 30 days prior to inclusion in this study
11. Congenital heart disease (except PFO, PDA or ASD)
12. Heart Failure due to confirmed amyloid or other restrictive cardiomyopathies
13. Chronic renal insufficiency defined by Creatinine ≥ 3.0 mg/dL or chronic renal replacement therapy
14. Any therapeutic invasive cardiac procedure within 30 days prior to index procedure
15. Any cardiac surgery, within 3 months prior to inclusion in the study
16. Cerebrovascular Accident (CVA) within 90 days prior to inclusion in this study
17. Thrombocytopenia (Platelet count\< 100,000/mm3) or thrombocytosis (Platelet count \> 750,000/mm3)
18. Body temperature \>38°C within 3 days prior to index procedure
19. Bleeding disorders or hypercoagulable state
20. Active peptic ulcer or active gastrointestinal (GI) bleeding within 90 days of the scheduled implant
21. Contraindication to anticoagulants or antiplatelet agents
22. Known allergy to stainless steel, nickel, titanium or contrast agents that cannot be adequately pre-medicated
23. Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically
24. Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
25. Co-morbid condition(s) that, in the opinion of the Investigator, limit life expectancy to \< 12 months
26. Co-morbid condition(s) that, in the opinion of the investigator, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
27. Pregnancy

Where it's running

• Rambam Medical Center
  Haifa, Israel Recruiting
• Tzafon Medical Center
  Poria – Neve Oved, Israel Recruiting
• Shamir Medical Center
  Be’er Ya‘aqov, Israel Not yet recruiting
• Hadassah Medical Center
  Jerusalem, Israel Not yet recruiting
• Rabin Medical Center
  Petah Tikva, Israel Not yet recruiting

Study contacts

• Study coordinator: Tami Abudi, +972
• Email: tami.a@cardiacsuccess.com
• Phone: +972 (52) 5989833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Yoga-based cardiac rehabilitation for heart failure with reduced ejection fraction

  This trial tests whether a yoga-based rehabilitation program can help people with heart failure and reduced ejection fraction compared with an educational program.

  Recruiting at 12 sites Centre for Chronic Disease Control, India · Dharwad, Karnataka and 15 other locations · NCT07817589

• Lumacaftor to improve cerebral blood flow in heart failure with reduced ejection fraction

  This study tests whether lumacaftor can improve brain blood flow and thinking abilities in adults with a certain type of heart failure.

  Recruiting Phase 2 Qanatpharma AG · Toronto, Ontario and 1 other locations · NCT07695090

• Stepwise withdrawal of ARNI and SGLT2i in HF with normalized ejection fraction

  This trial tests whether gradually stopping ARNI and SGLT2i is safe for people whose heart function has recovered after fixing a reversible heart‑disease cause.

  Recruiting Phase 4 Keimyung University Dongsan Medical Center · Daegu, Daegu and 4 other locations · NCT07631156

• Ring-style blood pressure bracelet test compared with 24-hour monitoring in people with HFrEF

  A ring-type blood pressure device is being tested to see if its 24-hour readings match those from standard ambulatory monitoring in adults with heart failure and reduced ejection fraction.

  Recruiting Keimyung University Dongsan Medical Center · Daegu · NCT07626879

• Diet and exercise plan to help people with heart failure and preserved heart function.

  This study tests whether a DASH-style, high-protein diet, resistance exercise, or both can help build muscle and improve fitness and quality of life in people with heart failure and reduced ejection fraction.

  Recruiting Medical University of Silesia · Zabrze, Silesian Voivodeship · NCT07595809

• HFrEF polypill strategy in Sri Lanka

  This study tests whether giving a heart failure polypill can reduce death from heart disease and hospitalizations in adults with HFrEF in Sri Lanka, compared with usual care.

  Recruiting at 10 sites Phase 3 Washington University School of Medicine · Kandy, Central Province and 11 other locations · NCT07569640

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.